Search

Amphastar Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

23.58 -0.25

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

23.47

Max

23.8

Schlüsselkennzahlen

By Trading Economics

Einkommen

24M

30M

Verkäufe

13M

184M

KGV

Branchendurchschnitt

14.148

56.432

EPS

0.8

Gewinnspanne

16.502

Angestellte

1,976

EBITDA

12M

45M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

-6.15% downside

Dividenden

By Acuity

Nächstes Ergebnis

5. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

171M

1B

Vorheriger Eröffnungskurs

23.83

Vorheriger Schlusskurs

23.58

Nachrichtenstimmung

By Acuity

40%

60%

120 / 339 Ranking in Healthcare

Amphastar Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Sept. 2026, 23:31 UTC

Amphastar Pharmaceuticals, Inc. is trading lower in after-market hours, continuing a trend of losses with the last three sessions closing lower.

16. Sept. 2026, 19:43 UTC

Amphastar Pharmaceuticals, Inc. is advancing, having peaked earlier in the session, and remains above its 20-day moving average near the upper end of its one-month range.

10. Sept. 2026, 20:01 UTC

Amphastar Pharmaceuticals shares are higher Thursday, despite earlier session pullbacks. No specific news was identified to explain the price movement.

8. Sept. 2026, 20:01 UTC

News

Amphastar Pharmaceuticals is lower today amid a decline in the Pharmaceuticals sub-sector. Analysts recommend "Reduce," with Bank of America reiterating an “underperform” rating.

4. Sept. 2026, 20:07 UTC

Amphastar Pharmaceuticals is lower today amid broader market declines following a strong jobs report, which has increased selling pressure across risk assets.

3. Sept. 2026, 19:56 UTC

Amphastar Pharmaceuticals is trading roughly flat amid broader market fluctuations. Treasury yields declined following initial jobless claims data that exceeded expectations.

2. Sept. 2026, 20:08 UTC

Amphastar Pharmaceuticals is advancing during Wednesday's session, despite earlier pulling back from a session high. No specific news was identified to explain the movement.

26. Aug. 2026, 20:08 UTC

Amphastar Pharmaceuticals is trading higher today, reflecting a broader market trend amid mixed performance following recent inflation data. The stock remains near its one-month range.

25. Aug. 2026, 20:07 UTC

Amphastar Pharmaceuticals is higher during Tuesday's session, reflecting a recovery after three consecutive lower finishes amid easing Treasury yields and falling oil prices.

24. Aug. 2026, 21:01 UTC

Amphastar Pharmaceuticals shares are lower in after-market hours, continuing a five-session decline. No specific news was identified to explain the price movement.

21. Aug. 2026, 19:56 UTC

Amphastar Pharmaceuticals Inc shares are lower today, despite earlier fluctuations. No specific news has been identified to explain the price movement.

20. Aug. 2026, 19:51 UTC

Amphastar Pharmaceuticals shares are higher, supported by a positive market environment and economic indicators showing strength in the broader economy.

19. Aug. 2026, 19:36 UTC

News

Barclays raised its price target on Amphastar Pharmaceuticals to $23.00, contributing to positive sentiment as shares remain well above their 20-day moving average.

18. Aug. 2026, 19:16 UTC

Amphastar Pharmaceuticals Inc shares are higher today, reflecting market volatility amid rising U.S. Treasury yields and inflation concerns linked to geopolitical tensions.

17. Aug. 2026, 19:16 UTC

Amphastar Pharmaceuticals Inc. shares are lower amid routine market fluctuations and concerns over slowing growth following declines in U.S. retail sales and consumer sentiment.

14. Aug. 2026, 20:01 UTC

Amphastar Pharmaceuticals is trading higher, rebounding from an early session low. The stock remains above its 20-day moving average despite no specific news.

12. Aug. 2026, 20:06 UTC

Amphastar Pharmaceuticals Inc shares are lower in Wednesday's session, continuing a decline from Tuesday's close amid fluctuating U.S. Treasury yields and inflation data.

11. Aug. 2026, 19:56 UTC

News

Amphastar Pharmaceuticals reported Q2 revenue of $183.9 million, exceeding expectations. Shares are modestly higher amid strong demand for key products and new launches.

10. Aug. 2026, 19:36 UTC

News

Amphastar Pharmaceuticals reported Q2 earnings of $0.70 per share on $183.9 million in revenue, but shares are trading lower today amid a slight net income decline.

7. Aug. 2026, 19:51 UTC

News

Amphastar Pharmaceuticals reported Q2 EPS of $0.91, exceeding estimates. Revenue also surpassed expectations, contributing to a positive market response and higher shares.

6. Aug. 2026, 23:02 UTC

News

Amphastar Pharmaceuticals reported second-quarter sales of $183.9 million, exceeding expectations. Shares are trading higher in after-market hours following the strong results.

4. Aug. 2026, 19:51 UTC

Amphastar Pharmaceuticals is trading lower today, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

3. Aug. 2026, 19:46 UTC

Amphastar Pharmaceuticals Inc is trading higher, reaching a session high amid positive market conditions and falling oil prices influencing investor sentiment.

31. Juli 2026, 19:36 UTC

Amphastar Pharmaceuticals is declining today, continuing a downward trend since Thursday. The stock reached a session low earlier this morning amid broader market volatility.

30. Juli 2026, 19:28 UTC

Amphastar Pharmaceuticals Inc. shares are lower amid significant downward pressure in the Pharmaceuticals sub-sector, reflecting broader sector weakness during Thursday's session.

29. Juli 2026, 20:41 UTC

Amphastar Pharmaceuticals shares are lower in after-market trading, continuing a decline amid rising crude oil prices and geopolitical tensions in the Middle East.

28. Juli 2026, 20:02 UTC

Amphastar Pharmaceuticals shares are higher today, diverging from a broader market decline amid a sell-off in technology stocks across Asian markets.

24. Juli 2026, 19:06 UTC

Amphastar Pharmaceuticals is trading higher, supported by a pullback in crude oil prices, which has eased some inflationary pressures affecting investor sentiment.

22. Juli 2026, 20:06 UTC

Amphastar Pharmaceuticals Inc shares are lower today, continuing a four-session decline amid market uncertainty ahead of the Federal Reserve meeting on July 29.

21. Juli 2026, 19:46 UTC

Amphastar Pharmaceuticals Inc is trading lower, continuing a three-session decline. No specific news was identified to explain the stock's performance.

Peer-Vergleich

Kursveränderung

Amphastar Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

-6.15% Nachteil

12-Monats-Prognose

Durchschnitt 22.167 USD  -6.15%

Hoch 30 USD

Tief 20 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Amphastar Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

6 ratings

0

Buy

5

Halten

1

Sell

Stimmung

By Acuity

120 / 339 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.